IN2013MU01868A - - Google Patents

Download PDF

Info

Publication number
IN2013MU01868A
IN2013MU01868A IN1868MU2013A IN2013MU01868A IN 2013MU01868 A IN2013MU01868 A IN 2013MU01868A IN 1868MU2013 A IN1868MU2013 A IN 1868MU2013A IN 2013MU01868 A IN2013MU01868 A IN 2013MU01868A
Authority
IN
India
Prior art keywords
component
relates
release
formulations
extended release
Prior art date
Application number
Other languages
English (en)
Inventor
Sushrut Krishnaji Kulkarni
Ajay Kumar Handa
Amit Om Prakash Gupta
Prudhvi Raju Dantuluri
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN1868MU2013 priority Critical patent/IN2013MU01868A/en
Priority to US14/287,787 priority patent/US20140348931A1/en
Publication of IN2013MU01868A publication Critical patent/IN2013MU01868A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1868MU2013 2013-05-27 2013-05-27 IN2013MU01868A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN1868MU2013 IN2013MU01868A (es) 2013-05-27 2013-05-27
US14/287,787 US20140348931A1 (en) 2013-05-27 2014-05-27 Sustained-release topiramate formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1868MU2013 IN2013MU01868A (es) 2013-05-27 2013-05-27

Publications (1)

Publication Number Publication Date
IN2013MU01868A true IN2013MU01868A (es) 2015-06-26

Family

ID=51935538

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1868MU2013 IN2013MU01868A (es) 2013-05-27 2013-05-27

Country Status (2)

Country Link
US (1) US20140348931A1 (es)
IN (1) IN2013MU01868A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586871B (zh) * 2014-12-27 2018-01-16 北京罗诺强施医药技术研发中心有限公司 包含托吡酯的药物组合物
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292700A1 (en) * 1997-04-21 2008-11-27 Biovail Laboratories Controlled release formulations using intelligent polymers
US8298576B2 (en) * 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate

Also Published As

Publication number Publication date
US20140348931A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
PH12016502552A1 (en) Formulation comprising a gemcitabine-prodrug
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020000333A (es) Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY191357A (en) Sustained-release dosage forms of ruxolitinib
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
IN2013MU03583A (es)
IN2014MN02236A (es)
WO2015033302A3 (en) Fulvestrant compositions
PH12016501841A1 (en) Immunosuppressant formulation
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
PH12017502149A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
MX2018005035A (es) Formulaciones de liberacion sostenida de anestesicos locales.
MX2016004078A (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
IN2013MU01868A (es)
MX2017013879A (es) Composiciones que comprenden anakinra.
IN2013CH05288A (es)
PH12017501979A1 (en) Pharmaceutical compound
WO2013168179A3 (en) Controlled release pharmaceutical formulations of antiviral agents